)
Korsana Biosciences (KRSA) investor relations material
Korsana Biosciences Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Special meeting set for Nov. 13, 2026, online; shareholders will vote on moving the legal domicile from Massachusetts to the Cayman Islands and adopting Cayman governing documents.
A similar proposal failed Aug. 26 despite 61.8% of votes cast in favor: turnout left support below the required thresholds. The Board resubmitted it after the Sept. 8 merger and concurrent private placement.
If approved, the same legal entity, business, management, assets and liabilities continue; Nasdaq trading under KRSA is expected to continue without interruption, except for a new CUSIP.
Voting matters and shareholder proposals
Proposal 1 requires at least two-thirds of all 45,541,358 outstanding voting shares, or 30,360,906 affirmative votes; abstentions and failures to vote count against it.
Proposal 2 requires two-thirds of votes properly cast; Proposal 3, authorizing adjournment to solicit votes if needed, requires more votes for than against.
Proposals 1 and 2 are interdependent; both must pass for redomestication. The Board unanimously recommends FOR all three proposals.
Record date is Oct. 7, 2026; online, telephone and internet voting closes Nov. 12 at 11:59 p.m. ET. The meeting is Nov. 13 at 10:30 a.m. ET.
Board of directors and corporate governance
Proposed Cayman Articles create a six-member board divided into three classes with staggered three-year terms; directors are elected by plurality, replacing annual elections.
While at least 30% of originally issued Series B preferred shares remain outstanding, holders may elect four directors, each with three board votes; this right carries over from current terms.
Under the Cayman Articles, directors may generally be removed only for cause; board vacancies are normally filled by remaining directors rather than shareholders.
Holders of 40% of paid-up voting share capital may requisition a general meeting, subject to procedural requirements; shareholder proposals and nominations face advance-notice and disclosure rules.
- CYC-126 advances toward Phase 2, but funding is needed beyond mid-2026.KRSA
Q4 2025 - Board seeks annual say-on-pay votes; March 2025 private placement raised $1.375 million.KRSA
Proxy filing - $2.9M cash runway into mid-2025, with substantial doubt over continued operations.KRSA
Q3 2024 - A $25M shelf backs a CNS-focused portfolio shift amid substantial financing risk.KRSA
Registration filing - A potential TRD pipeline anchors strategy as resale shares bring no proceeds and going-concern risks persist.KRSA
Registration filing - TRD pipeline pivot faces an urgent funding need and substantial going-concern doubt.KRSA
Q4 2024 - Lower losses, but a $4.6M cash balance and funding needs leave substantial going-concern doubt.KRSA
Q2 2024 - A renewed Cayman redomestication vote could reshape governance and shareholder protections.KRSA
Proxy filing - TRD pivot advances, but $4.6m cash and funding uncertainty constrain the runway.KRSA
Q3 2025
Next Korsana Biosciences earnings date
Next Korsana Biosciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage
)